In HCC cells LCL-PI 11 and HLE, the treatment of 5-aza-2′-deoxycytidine (5-AZA-CdR) decreased gene expressions of DNMT1, DNMT3a, and DNMT3b and increased GSTP1 and SOCS1 [32,33]. This evidence concerns the gene DNMT3B and hepatocellular carcinoma.